ProPhase Labs to Present at Two Upcoming August Conferences
August 16 2021 - 8:30AM
ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and
genomics company, today announced that Chairman and CEO Ted Karkus
is scheduled to present at the following investor conferences:
Q3 Investor Summit: August 17 – 18,
2021
Mr. Karkus will deliver his corporate
presentation on August 17, 2021 at 11:00 am ET.
Management will be available for
one-on-one meetings to be held throughout the conference.
Investors can register here: Q3
Investor Summit Investor Registration
SNN Network Summer Virtual Event Investor
Conference: August 17 – 19, 2021
Mr. Karkus will deliver his corporate
presentation on August 18, 2021 at 2:00 pm ET.
Management will be available for
one-on-one meetings to be held throughout the conference.
Investors can register here:
REGISTER
About ProPhase
Labs
ProPhase Labs (Nasdaq: PRPH) (“ProPhase”) is a
diversified biotech and genomics company that seeks to leverage its
CLIA lab services to provide whole genome sequencing and research
direct to consumers and also build a genomics data base to be used
for further research including clinical studies. The Company
continues to provide traditional CLIA molecular laboratory
services, including COVID-19 testing. ProPhase Precision Medicine,
Inc., focuses on genomics testing technologies, a comprehensive
method for analyzing entire genomes, including the genes and
chromosomes in DNA. The data obtained from genomic testing can help
to identify inherited disorders and tendencies, help predict
disease risk, help identify expected drug response, and
characterize genetic mutations, including those that drive cancer
progression.
ProPhase Diagnostics offers a broad array of
clinical diagnostic and testing services at its CLIA certified
laboratories. ProPhase Diagnostics serves patients who may have
SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods.
Critical to COVID testing, results are provided in under 24 hours.
ProPhase Diagnostics also offers PCR (polymerase chain reaction)
testing for Influenzas A and B and RSV; as well as antigen and
antibody/immunity tests to broaden its COVID-19 testing beyond
RT-PCR testing.
ProPhase Global Healthcare, Inc. was formed to
seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into
other countries and to pursue additional healthcare-related
initiatives.
ProPhase Labs has decades of experience
researching, developing, manufacturing, distributing, marketing,
and selling OTC consumer healthcare products and dietary
supplements, including dietary supplements under the TK
Supplements® brand. ProPhase actively pursues strategic
investments and acquisition opportunities for other companies,
technologies, and products. For more information,
visit www.ProPhaseLabs.com.
Contact:
CORE IRJules Abraham917-885-7378julesa@coreir.com
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Apr 2023 to Apr 2024